AI continues to gain momentum in the biopharmaceutical industry in 2023
Pharmaceutical Technology
JANUARY 16, 2023
January, 2023
296 
Biotech CFOs eye research cuts, partnerships amid sector retrenchment: report
Bio Pharma Dive
JANUARY 30, 2023
The report, a yearly poll of 100 financing executives by accounting and consulting firm BDO, revealed the many levers young drugmakers are pulling to conserve cash
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Pharma Mirror Q&A with Jane Myles, Vice President of Clinical Trial Innovation at Curebase
Pharma Mirror
JANUARY 23, 2023
The White House Office of Science & Technology Policy (OSTP) convened a listening session January 11.
FDA pulls AZ’s Evusheld for COVID, citing lack of efficacy
Pharma Phorum
JANUARY 27, 2023
AstraZeneca’s revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against most subvariants now circulating in the US.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
A Holiday Surprise; FTC Published Its Health Products Compliance Guidance
FDA Law Blog
JANUARY 10, 2023
By Riëtte van Laack & Ricardo Carvajal — On Dec. 20, 2022, FTC announced the publication of its Health Products Compliance Guidance (“new Guidance”).
BMS settles lawsuit with two fired employees who refused COVID vaccines
Fierce Pharma
JANUARY 26, 2023
BMS settles lawsuit with two fired employees who refused COVID vaccines kdunleavy Thu, 01/26/2023 - 14:30
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Large study of J&J’s HIV vaccine stopped after shot found ineffective
Bio Pharma Dive
JANUARY 18, 2023
The result from the nearly 4,000-person trial is the latest setback in a long-running effort to develop a safe and effective shot for HIV infections
Can You Sue Your Doctor for Blindness Caused by Elmiron®?
Pharma Mirror
JANUARY 31, 2023
The Janssen Pharmaceuticals-produced medication Elmiron® is used to treat interstitial cystitis. Elmiron may be connected to eye damage that results in vision loss or other negative effects like blurry vision, according to some studies.
Google and DeepMind share work on medical chatbot Med-PaLM
Pharma Phorum
JANUARY 6, 2023
Google and DeepMind have developed an artificial intelligence-powered chatbot tool called Med-PaLM designed to generate “safe and helpful answers” to questions posed by healthcare professionals and patients.
A Day in the Life of a Senior Art Director
Intouch Solutions
JANUARY 26, 2023
M eet Meg Bradley, Senior Art Director at EVERSANA INTOUCH. Meg has been with EVERSANA INTOUCH for more than 5 years and has held a variety of positions.
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
New patent expiration for Merck Sharp drug JANUMET
Drug Patent Watch
JANUARY 25, 2023
Annual Drug Patent Expirations for JANUMET Janumet is a drug marketed by Merck Sharp Dohme and is included in two NDAs. It is available from two suppliers. There are four… The post New patent expiration for Merck Sharp drug JANUMET appeared first on DrugPatentWatch - Make Better Decisions.
Health Canada gives approval to Enhertu for breast cancer treatment
Pharmaceutical Technology
JANUARY 13, 2023
Health Canada has granted approval to Enhertu (trastuzumab deruxtecan) to treat unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.
Three VCs launch Dimension, a new firm with plans to fuel biotech’s ‘digitization’
Bio Pharma Dive
JANUARY 25, 2023
The veteran investors see the marriage of tech and life sciences as the “largest opportunity in venture today,” said co-founder and former Lux Capital general partner Adam Goulburn
FIP advances sustainable health systems by providing new guidance for self-managing reflux symptoms
Pharma Mirror
JANUARY 30, 2023
The Hague, 25 January 2023 — Managing symptoms of reflux is the topic of new quick reference guidance for pharmacists published by the International Pharmaceutical Federation (FIP) today.
An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
A new dawn of the genomic age: five areas set to be transformed in 2023
Pharma Phorum
JANUARY 26, 2023
2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.
Amvuttra recommended by NICE for amyloidosis
Pharma Times
JANUARY 19, 2023
Therapy is among the first to receive a positive draft recommendation under streamlined pilot process
New patent expiration for Merck Sharp drug JANUVIA
Drug Patent Watch
JANUARY 25, 2023
Annual Drug Patent Expirations for JANUVIA Januvia is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from three suppliers. There are three… The post New patent expiration for Merck Sharp drug JANUVIA appeared first on DrugPatentWatch - Make Better Decisions.
Can the FDA keep the momentum going for rare disease drug approvals?
Pharmaceutical Technology
JANUARY 22, 2023
In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. However, while only around 34% of the approvals in 2018 were for orphan drugs, 54% new approvals in 2022 were for drugs to treat rare diseases.
Mandatory COVID Vaccination Policy Template
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
5 FDA decisions to watch in the first quarter
Bio Pharma Dive
JANUARY 9, 2023
An Alzheimer’s drug from Eli Lilly, BioMarin’s hemophilia gene therapy and a new type of breast cancer treatment are among the top decisions on the agency’s docket through the end of March
Experts advise European SME packaging firms to expand or seek acquisition prior to Pharmapack Europe
Pharma Mirror
JANUARY 30, 2023
The importance of AI literacy in life sciences
Pharma Phorum
JANUARY 13, 2023
The promise and value of artificial intelligence (AI) in life sciences are somewhat obscured by the over-generalisation of this technology.
Incurable liver disease may prove curable
The Pharma Data
JANUARY 5, 2023
Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the liver, could be reversed with a single drug.
New patent expiration for Merck Sharp drug JUVISYNC
Drug Patent Watch
JANUARY 25, 2023
Annual Drug Patent Expirations for JUVISYNC Juvisync is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are four patents protecting this drug and three… The post New patent expiration for Merck Sharp drug JUVISYNC appeared first on DrugPatentWatch - Make Better Decisions.
CARsgen and Huadong Medicine to commercialise CT053 in mainland China
Pharmaceutical Technology
JANUARY 16, 2023
CARsgen Therapeutics has announced a col labor ation with Huadong Medicine to commercialise zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China.
Al Sandrock on his short retirement and taking on a biotech turnaround project
Bio Pharma Dive
JANUARY 17, 2023
In a conversation at the J.P. Morgan Healthcare conference, the longtime Biogen executive discussed his hesitance to jump back into an executive role and why an opportunity to run Voyager Therapeutics drew him in
APAC overview: trends, challenges, and possibilities for growth in the MarTech sector
Pharma Mirror
JANUARY 26, 2023
by Dodie Guadines, Viseven Regional Director, APAC Region In 2022 the APAC pharmaceutical market was estimated at $40.25 billion. At the same time, Asia-Pacific pharma players expect their businesses to grow rapidly in the upcoming year.
Bayer taps Google’s quantum power for drug discovery
Pharma Phorum
JANUARY 12, 2023
Bayer has signed an agreement with Google aimed at using high-level processing power to handle quantum chemistry calculations used to predict the chemical and physical properties of drug molecules at the atomic scale.
Celadon receives good manufacturing practice approval
Pharma Times
JANUARY 16, 2023
MHRA approval relates to the company’s midlands-based drug development facilities
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
The Pharma Data
JANUARY 4, 2023
Gilead Receives Rights to Exclusively License EVOQ’s NanoDisc Technology to Develop and Commercialize Immunotherapy Products for Rheumatoid Arthritis and Lupus –. Gilead Sciences, Inc. Nasdaq: GILD) and EVOQ Therapeutics , Inc.
Are we entering the era of biologics for COPD?
Pharmaceutical Technology
JANUARY 8, 2023
In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma.
Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant
Bio Pharma Dive
JANUARY 23, 2023
This year could stay turbulent for the biotech sector as investors look for what the Roivant CEO described in an interview with BioPharma Dive as “safe harbors in a storm &rdquo
AI and the Big Data paradigm – big ambitions in novel drug discovery
Pharma Phorum
JANUARY 11, 2023
Over the past few decades, data generation has veritably exploded. However, the ‘Big Data paradigm’ is not so much concerned with the volume of that data, but how businesses and, indeed, industries can derive meaningful insights from what has become a glut of information.
Let's personalize your content